This study is currently not recruiting participants.

Phase II study of Rolapitant plus Olanzapine Palonosetron and Dexamethasone in Patients with Germ Cell Tumors undergoing 5-day Cisplatin-based Chemotherapy

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

The purpose of this study is to test whether the drug rolapitant, an NK-1 Receptor Antagonist (NK1RA), (a drug used for the prevention of nausea [upset stomach] and vomiting caused by chemotherapy) can reduce symptoms of nausea and vomiting in patients with germ cell cancer that are receiving standard treatment with 5-day Cisplatin-based chemotherapy.

Description

This is a prospective, single-arm phase II study in subjects with Metastatic germ cell cancer. This study will test whether the drug rolapitant, a NK-1 Receptor Antagonist (NK1RA), (a drug used for the prevention of nausea [upset stomach] and vomiting caused by chemotherapy) can reduce symptoms of nausea and vomiting in patients with germ cell cancer that are receiving standard treatment with 5-day Cisplatin-based chemotherapy.

Details
Condition Germ Cell Tumor
Age 18years - 100years
Clinical Study IdentifierTX8715
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.